Abstract
There is a global increase in the prevalence of cardiovascular disease underscoring the need for new therapeutic strategies. Gene therapy is a promising approach, but inefficient gene delivery to the human heart remains a major barrier to clinical translation. Substantial efforts have focused on improving cardiac gene delivery through vector modifications and cardiac-targeted delivery methods. These advances have improved gene uptake efficiency and cardiac specificity in preclinical studies, and several strategies are now undergoing clinical evaluation. In this review, we provide an overview of current therapeutic vectors and delivery modalities for cardiac gene therapy, including preclinical development and clinical investigation.